OMass logo.png
OMass Therapeutics Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate Against MC2
01. Oktober 2024 02:30 ET | OMass Therapeutics
PRESS RELEASE OMass Therapeutics Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate Against MC2 Oxford, United Kingdom – 1 October 2024 –...
OMass logo.png
OMass Therapeutics Selected by Fierce Biotech as a “Fierce 15” Winner for 2024
05. August 2024 09:08 ET | OMass Therapeutics
PRESS RELEASE OMass Therapeutics Selected by Fierce Biotech as a “Fierce 15” Winner for 2024 Oxford, United Kingdom – 5th August 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology...
OMass logo.png
OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann
08. April 2024 04:00 ET | OMass Therapeutics
PRESS RELEASE OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a...
OMass logo.png
OMass Therapeutics expands leadership team with the appointment of Melissa Faris as Chief Business Officer
15. November 2023 02:00 ET | OMass Therapeutics
PRESS RELEASE OMass Therapeutics expands leadership team with the appointment of Melissa Faris as Chief Business Officer Oxford, United Kingdom – 15 November 2023 – OMass Therapeutics (‘OMass’ or...
OMass logo.png
OMass Therapeutics Adds Mark Namchuk, PhD to Scientific Advisory Board
26. September 2023 02:00 ET | OMass Therapeutics
PRESS RELEASE OMass Therapeutics Adds Mark Namchuk, PhD to Scientific Advisory Board Oxford, United Kingdom – 26th September 2023 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology...
OMass logo.png
OMass Therapeutics Expands Leadership Team with Two New Appointments
02. August 2023 02:00 ET | OMass Therapeutics
PRESS RELEASE OMass Therapeutics Expands Leadership Team with Two New Appointments Appointment of two senior executives in newly created rolesPeter Phillips M.D., Ph.D. joins as Senior Vice...
OMass logo.png
OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension
15. Mai 2023 02:00 ET | OMass Therapeutics
PRESS RELEASE OMass Therapeutics Announces Appointment of New Board Chairand Series B Extension Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from...
OMass logo.png
OMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio Progress
19. April 2023 02:00 ET | OMass Therapeutics
PRESS RELEASE OMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio Progress Move to new purpose-built 16,000ft2 flagship site on ARC...
OMass logo.png
Publication in Nature Chemistry Demonstrates the Benefits of Native Mass Spectrometry in the Interrogation of Target Ecosystems and Drug Discovery
10. November 2022 11:00 ET | OMass Therapeutics
PRESS RELEASE Publication in Nature Chemistry Demonstrates the Benefits of Native Mass Spectrometry in the Interrogation of Target Ecosystems and Drug Discovery Joint publication in Nature...
OMass logo.png
OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases
28. April 2022 02:00 ET | OMass Therapeutics
PRESS RELEASE OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases Financing led by new investors, GV, Northpond Ventures and Sanofi...